Overview
Sponsor-declared trial summary
Phase
Human pharmacology (Phase I) - First administration to humans
Status
Authorised, recruiting
Participants planned
130
Countries
1
Sites
1
Healthy volunteers
Key facts
- Sponsor
- Arcus Biosciences Inc.
- Participant type
- Healthy volunteers
- Age range
- 18-64 years
- Gender
- Male and Female
- Therapeutic area
- Diseases [C] - Skin and Connective Tissue Diseases [C17]
- Trial duration
- 26 Jun 2026 → ongoing
- Decision date (initial)
- 2026-06-16
- Transition trial
- No
- Low-intervention
- No
- Rare-disease indication
- No
- Vulnerable population
- Yes
Trial design
CTIS Part I — objectives, methods, condition coding
Conditions and MedDRA coding
Healthy volunteers
Sponsors and contacts
Sponsor organisations, regulatory contacts, third parties
Arcus Biosciences Inc.
- Sponsor organisation
- Arcus Biosciences Inc.
- Address
- 3928 Point Eden Way
- City
- Hayward
- Postcode
- 94545-3719
- Country
- United States
Scientific contact point
- Organisation
- Arcus Biosciences Inc.
- Contact name
- Medical Director
Public contact point
- Organisation
- Arcus Biosciences Inc.
- Contact name
- Medical Director
Locations
1 EU/EEA country · 1 investigational sites
By country
| Country | MS status | Planned subjects | Sites |
|---|---|---|---|
| Netherlands | Authorised, recruiting | 130 | 1 |
| Rest of world | — | 0 | — |
Investigational sites
Pharmaceutical Research Associates Group B.V.
Program Management, Van Swietenlaan 6, 9728 NZ, Groningen
Country notifications
Trial-start, recruitment-start, end and early-termination notifications submitted per Member State
| Country | Trial start | Trial end | Recruitment start | Recruitment end | Early termination |
|---|---|---|---|---|---|
| Netherlands | 2026-06-26 |
Application history
1 submissions — initial application plus substantial / non-substantial modifications
| # | Type | Code | Submitted | Reference MS | Conclusion | Decision date |
|---|---|---|---|---|---|---|
| 1 | INITIAL | IN | 2026-05-04 | Netherlands | Acceptable 2026-06-16
|
2026-06-16 |